What is HTG Molecular Diagnostics, Inc. (HTGMQ) stock price today?

HTG Molecular Diagnostics, Inc. (HTGMQ) is currently trading at $0.00.

What is HTGMQ P/E ratio?

HTG Molecular Diagnostics, Inc.'s P/E ratio is 0.00. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is HTGMQ return on equity (ROE)?

HTG Molecular Diagnostics, Inc.'s return on equity (ROE) is -440.00%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is HTG Molecular Diagnostics, Inc.'s market cap?

HTG Molecular Diagnostics, Inc. has a market capitalization of $221.

OTC · Medical - Diagnostics & Research

HTG Molecular Diagnostics, Inc. (HTGMQ) Stock

$0.00 OTC: HTGMQ Healthcare

HTG Molecular Diagnostics, Inc. operates as a life sciences company, specializing in the realm of precision medicine.

Valuation

Metric	Value
Price	$0.00
Market Cap	$221
P/E Ratio	0.00
P/B Ratio	0.00
P/S Ratio	0.00
EPS (TTM)	$-24.28
52-Week High	$0.00
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-440.00%
ROA	-122.22%
ROCE	-219.10%
Gross Margin	-350.00%
Operating Margin	-350.00%
Net Margin	-366.67%
Debt/Equity	1.60
Current Ratio	2.00

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$22.0M	$19.0M	$9.0M	$9.0M	$6.0M
Operating Profit	$-16.0M	$-19.0M	$-20.0M	$-18.0M	$-21.0M
Net Profit	$-16.0M	$-19.0M	$-21.0M	$-17.0M	$-22.0M
EPS	$-107.61	$-91.17	$-54.12	$-29.66	$-24.28
Op Margin	-75.2%	-98.7%	-229.1%	-200.1%	-327.2%

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$44.0M	$45.0M	$35.0M	$30.0M	$18.0M
Total Liabilities	$23.0M	$21.0M	$21.0M	$20.0M	$12.0M
Cash	$8.0M	$8.0M	$22.0M	$10.0M	$12.0M
Borrowings	$10.0M	$11.0M	$13.0M	$12.0M	$8.0M

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$-13.0M	$-17.0M	$-16.0M	$-17.0M	$-18.0M
Investing Cash Flow	$-24.0M	$-5.0M	$18.0M	$-7.0M	$12.0M
Financing Cash Flow	$-1.0M	$-1.0M	$0	$0	$16.0M
Net Cash Flow	$2.0M	$-1.0M	$12.0M	$-13.0M	$3.0M
Free Cash Flow	$-14.0M	$-18.0M	$-17.0M	$-17.0M	$-18.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.19
FCF Yield	-8339744.34%
Quick Ratio	1.78
Interest Coverage	-24.31
Return 1Y	0.00%
Return 3Y	-99.98%
Return 5Y	—

Ownership

Insiders Held0.02%

Institutions Held0.00%

Institutions Float Held0.00%

Institutional Holder	Shares	Report Date
Morgan Stanley	884	2023-03-31
Wells Fargo & Company	13	2023-03-31
Royal Bank of Canada	10	2023-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BIOCQBiocept, Inc.	$0.00	—	-0.01	$263	0.00%
BRSFBrain Scientific Inc.	$0.00	—	0.00	$746	0.00%
BSPMBiostar Pharmaceuticals, Inc.	$0.00	—	0.00	$264	0.00%
CLVRClever Leaves Holdings Inc.	$0.00	—	0.00	$175	0.00%
CRFTFBC Craft Supply Co. Ltd.	$0.00	—	0.00	$23	0.00%

About HTG Molecular Diagnostics, Inc.

HTG Molecular Diagnostics, Inc. operates as a life sciences company, specializing in the realm of precision medicine. They furnish specialized instruments, consumable products, and software applications engineered to automate the processing of samples and characterize a variety of molecular targets. Among their portfolio of molecular profiling panels are offerings like the HTG Transcriptome Panel, HTG EdgeSeq precision immuno-oncology panel, HTG EdgeSeq miRNA whole-transcriptome assay, HTG EdgeSeq DLBCL cell of origin assay EU, HTG EdgeSeq Oncology Biomarker Panel, HTG immune response panel, and the HTG mouse mRNA tumor response panel. The company handles direct distribution of its instruments and consumables across the United States and Europe, supplementing this with a network of distributors for other parts of Europe and global markets. Its customer base primarily includes biopharmaceutical corporations, academic research institutions, and molecular testing laboratories. Incorporated in 1997 and based in Tucson, Arizona, the entity was formerly known as HTG, Inc., adopting its current name, HTG Molecular Diagnostics, Inc., in March 2011. However, on June 5, 2023, HTG Molecular Diagnostics, Inc. initiated a voluntary Chapter 11 reorganization filing with the U.S. Bankruptcy Court for the District of Delaware.

HTG Molecular Diagnostics, Inc. (HTGMQ) stock trades at $0.00 with a market capitalization of $221. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, HTG Molecular Diagnostics, Inc. generates a return on equity (ROE) of -440.00%, return on capital employed of -219.10%, an operating margin of -350.00%, a net profit margin of -366.67%.

Official website: www.htgmolecular.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides